Report Company Directory
- Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium by GlobeNewsWire
- Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split by GlobeNewsWire
- Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia by GlobeNewsWire
- Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision by GlobeNewsWire
- Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference by GlobeNewsWire
- Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial by GlobeNewsWire
- Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit by GlobeNewsWire
- Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress by GlobeNewsWire
- Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K by GlobeNewsWire
- Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI) by GlobeNewsWire
- Oranco, Inc. Officially Launches Blockchain-Powered Anti-Counterfeiting Laser Recognition Proprietary Technology and E-Commerce Trading Platform by GlobeNewsWire
- Oranco, Inc. to Launch Blockchain-based Anti-counterfeiting Laser Recognition Proprietary Technology by GlobeNewsWire
- Oranco, Inc. Reports Fiscal Year 2019 Financial Results by GlobeNewsWire
- Oranco, Inc. Releases 2019 Chairman Letter for Shareholders by GlobeNewsWire
- Oranco, Inc. Announces New Development in Blockchain-Based Liquor Identification and Collection Technology by GlobeNewsWire
- Oranco, Inc. announces increased revenues and net income for the six months ended December 31, 2018 by GlobeNewsWire
- Oranco, Inc. Reports Increased Revenues for First Quarter 2018 Financial Results by GlobeNewsWire
- A director sold 38,121,530 shares at 0.009USD and by SmartInsider
- Coffee, Croissants & Credit/Italgas, Kinder Morgan, Klepierre, Unibail, Balder, Swisscom, Telecom Italia, Equinix, RELX, Orange by ING Financial Markets
- Orange S.A. by CFRA Research
- Orange S.A. by CFRA Research
- Orange S.A. by CFRA Research
- Orange S.A. by CFRA Research
- Telecoms Outlook 2024: Stepping into the future by ING Financial Markets
- Orange S.A. by CFRA Research
- Orange S.A. by CFRA Research
- Orange S.A. by CFRA Research
- European telecom companies have been the underdog but prospects could be improving by ING Financial Markets
- CB weekly review by Exane Derivatives
- CB weekly review by Exane Derivatives
- Valorisations : la vigilance est de mise désormais by Exane Derivatives
- BT / Orange 0.375% 17/21: share settlement option active from tomorrow by Exane Derivatives
- Coffee, Croissants & Credit/Carrefour, Nestlé, Orange, EDF and utilities ratings by ING Financial Markets
- Coffee, Croissants & Credit/Austrian banks, Orange and Innogy by ING Financial Markets
- Coffee, Croissants & Credit/US presidential election result, Orange by ING Financial Markets
- Coffee, Croissants & Credit/Pernod Ricard, Telia and Orange by ING Financial Markets
- CB weekly review by Exane Derivatives
- CB weekly review by Exane Derivatives